Compare TCBK & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCBK | ANAB |
|---|---|---|
| Founded | 1975 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 1995 | 2015 |
| Metric | TCBK | ANAB |
|---|---|---|
| Price | $53.52 | $67.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 12 |
| Target Price | $54.60 | ★ $71.67 |
| AVG Volume (30 Days) | 159.4K | ★ 535.2K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | 6.94 | ★ 91.02 |
| EPS | ★ 1.04 | N/A |
| Revenue | $53,445,000.00 | ★ $234,603,000.00 |
| Revenue This Year | $12.03 | N/A |
| Revenue Next Year | $4.47 | $52.14 |
| P/E Ratio | $51.20 | ★ N/A |
| Revenue Growth | 4.12 | ★ 157.01 |
| 52 Week Low | $39.84 | $17.11 |
| 52 Week High | $54.17 | $73.30 |
| Indicator | TCBK | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 61.79 | 68.62 |
| Support Level | $48.57 | $52.32 |
| Resistance Level | N/A | $67.69 |
| Average True Range (ATR) | 1.04 | 3.32 |
| MACD | 0.17 | 1.47 |
| Stochastic Oscillator | 82.12 | 87.83 |
TriCo Bancshares is a California corporation organized to act as a bank holding company for Tri Counties Bank. The Bank is a California-chartered bank that is engaged in the general commercial and retail banking business in California counties. The Bank provides a breadth of personal, small business, and commercial financial services, including accepting demand, savings and time deposits and making small business, commercial, real estate, and consumer loans, as well as a range of treasury management services and other customary banking services including safe deposit boxes at some branches. The company's primary source of revenue is the net interest income.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).